NCT04997148View on ClinicalTrials.gov

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

CompletedOBSERVATIONAL

Enrollment

116

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

September 14, 2023

Study Completion Date

September 14, 2023

Conditions

Relapsing-Remitting Multiple Sclerosis

Trial Locations (8)

Unknown

University Hospitals Coventry and Warwickshire- Neurology, Coventry

NHS Lanarkshire Health Board- Department of Neurology, Glasgow

Queen Elizabeth University Hospital, Glasgow

University Hospitals of Leicester NHS Trust, Leicester

Barking Havering and Redbridge University Hospitals NHS Trust, London

University College London UCL, London

Nottingham City Hospital (2655), Nottingham

Salford Royal, Salford

All Listed Sponsors

collaborator

Merck Serono Limited, UK

INDUSTRY

lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04997148 - Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS) | Biotech Hunter | Biotech Hunter